drugset / Trial / NCT00585585

Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

NCT00585585

Phase 2 Terminated 1 enrolled University of Cincinnati
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.

Timeline

Start
2007-07
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Betahistine Small molecule 300 mg Oral